Track topics on Twitter Track topics that are important to you
To determine the optimal time to initiate anticoagulation with Direct Oral Anticoagulants (DOACs) following major hemorrhage in patients with non-valvular atrial fibrillation or VTE.
Primary Outcome: 60-day composite of thromboembolic events, defined as DVT, pulmonary emboli, myocardial infarctions, ischemic strokes and systemic emboli, and bleeding events defined as non-CNS major bleeding events (modified BARC3 or above 7) worsening index tICrH or new intracranial hemorrhage (ICrH).
To compare 60 day clinical outcomes by the modified Rankin scale among the time-to-treatment groups To compare 60 day clinical outcomes by the Glasgow Outcome Scale-Extended (GOS-E) among the time-to-treatment groups To explore the optimal timing in subgroups of age, sex, outcome category, and NOAC choice
The trial will employ an innovative adaptive design using time as a dose (1, 2 and 4 weeks) and adapting randomization probabilities to the better performing doses. Entry into the trial is driven pragmatically by clinician intent to restart a DOAC after any anticoagulant-associated tICrH and willingness randomize to the specified time intervals. We include as indication for anticoagulation atrial fibrillation and VTE. We exclude mechanical valves and ventricular assist devices (VADs) and the coronary and/or peripheral artery disease low-dose DOAC indication. As all groups are anticoagulated, we do not expect separation of event curves beyond 60 days. This is a secondary prevention trial, not a TBI treatment trial, and is thus powered on these events. However, we will also collect 90-day Glasgow Outcome Scale-Extended (GOS-E)and modified Rankin Scale (mRS) to explore weighting of the components of the composite, and we will perform a secondary analysis removing DVT, the lowest mortality event, from the thrombotic component. We will employ early stopping for futility or superiority of one arm (defined under statistical analysis plan). The sample size is 1,100 patients (expected 10% lost to follow up leaving 1,000 analyzable) which gives us 0.86 power at an alpha of 0.05 (based on expected thrombotic event rates of 3, 6 and 9% and bleeding rates of 1, 0.67 and 0.33% at 1, 2 and 4 weeks)). Restarting is limited to DOACs (though anticoagulant at index tICrH is not) as opposed to vitamin K antagonists (VKA). VKA delayed onset would confound a timing trial, and heparin bridging is not standard in atrial fibrillation, which we expect to be the majority indication. DOACs represented greater than half of 2018 trial network anticoagulated tICrH and are rapidly rising. The US Food and Drug Administration (FDA) approved aDOAC generic (apixaban) in 2019, likely accelerating uptake. DOACs are associated with lower overall ICrH risk. Excluding VKA acts as a check on mechanical valve or VAD enrollment, for which our time intervals may not be appropriate.
Not yet recruiting
University of Texas at Austin
Published on BioPortfolio: 2020-01-22T12:12:57-0500
Evaluation of efficacy and safety of recombinant factor VIIa versus standard therapy in preventing early haematoma growth in spontaneous acute intracerebral haemorrhage in patients treated...
This study was designed to assess the effectiveness of oral anticoagulants in elderly patients (>=75 years) with atrial fibrillation. All patients discharged from one large hospital in Sto...
Novel, non-vitamin K antagonist oral anticoagulants (NOAC) target selected players in the coagulation cascade as the direct thrombin inhibitor dabigatran and the factor Xa-inhibitors apixa...
The Chongqing intracerebral hemorrhage study is a multi-center, prospective, observational study led by professor Qi Li from Chongqing Medical University. Professor Peng Xie will be the se...
Hemorrhage remains the leading cause of maternal death worldwide. Tranexamic acid has been shown to reduce rates of hemorrhage when given prophylactically prior to cesarean delivery. It ha...
Perimesencephalic hemorrhage (PMH), a subtype of nonaneurysmal subarachnoid hemorrhage, is characterized by a typical pattern of localized hemorrhage on head CT. PMH is usually associated with a benig...
Predicting future hemorrhage risk may allow better selection of patients with cerebral cavernous malformations (CCMs) who will likely benefit from treatment. In this study, we sought to identify predi...
Among the elderly, use of antithrombotics (ATs), antiplatelets (APs; aspirin, clopidogrel), and/or anticoagulants (ACs; warfarin, direct oral ACs [DOACs; dabigatran, rivaroxaban, apixaban]) to prevent...
Intraventricular hemorrhage (IVH) is a verified independent prognostic parameter in patients with intracerebral hemorrhage (ICH). However, the impact of the extent of IVH on clinical outcomes is unest...
Terlipressin, somatostatin, or octreotide are recommended as pharmacologic treatment of acute variceal hemorrhage. Nonselective β-blockers decrease the risk of variceal hemorrhage and hepatic decompe...
Agents that affect the function of FIBRIN in BLOOD COAGULATION. They used as COAGULANTS for HEMORRHAGE or ANTICOAGULANTS for THROMBOSIS.
Hemorrhage within the orbital cavity, posterior to the eyeball.
Intraocular hemorrhage from the vessels of various tissues of the eye.
Hemorrhage following any surgical procedure. It may be immediate or delayed and is not restricted to the surgical wound.
The sudden loss of blood supply to the PITUITARY GLAND, leading to tissue NECROSIS and loss of function (PANHYPOPITUITARISM). The most common cause is hemorrhage or INFARCTION of a PITUITARY ADENOMA. It can also result from acute hemorrhage into SELLA TURCICA due to HEAD TRAUMA; INTRACRANIAL HYPERTENSION; or other acute effects of central nervous system hemorrhage. Clinical signs include severe HEADACHE; HYPOTENSION; bilateral visual disturbances; UNCONSCIOUSNESS; and COMA.
Pulmonary relating to or associated with the lungs eg Asthma, chronic bronchitis, emphysema, COPD, Cystic Fibrosis, Influenza, Lung Cancer, Pneumonia, Pulmonary Arterial Hypertension, Sleep Disorders etc Follow and track Lung Cancer News ...
Neurology - Central Nervous System (CNS)
Alzheimer's Disease Anesthesia Anxiety Disorders Autism Bipolar Disorders Dementia Epilepsy Multiple Sclerosis (MS) Neurology Pain Parkinson's Disease Sleep Disorders Neurology is the branch of me...